Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 5Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Venous Thromboembolism 1Multiple Myeloma 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × apixaban × Plasma cell × Clear all
NCT02958969 2019-12-17

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Dana-Farber Cancer Institute

Phase 4 Completed
50 enrolled 5 charts
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡